title: Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness.
abstract: Glioblastoma multiforme (GBM) is the most common primary brain tumor and is among the deadliest of human cancers. Dysregulation of microRNAs (miRNAs) expression is an important step in tumor progression as miRNAs can act as tumor suppressors or oncogenes and may affect cell sensitivity to chemotherapy. Whereas the oncogenic miR21 has been shown to be overexpressed in gliomas, the expression and function of the tumor-supressor miR200a in GBMs remains unknown. In this study, we show that miR21 is upregulated in grade IV (GBMs) vs. grade II-III (LGs) gliomas, confirming that miR21 expression level is correlated with tumor grade, and that it may be considered as a marker of tumor progression. Conversely, miR200a is demonstrated for the first time to be downregulated in GBMs compared with LGs, and overexpression of miR200a in GBM cells is shown to promote TMZ-sensitivity. Interestingly, miR200a but not miR21 expression level is significantly higher in TMZ-responsive vs. -unresponsive tumoral glial cells in primary culture. Furthermore, miR200a appears negatively correlated with the expression of the DNA repair enzyme O (6)-methylguanine methyltransferase (MGMT), and the inhibition of MGMT activity results in an increase of miR200a expression in GBM cells. Taken together, these data strongly suggest that miR200a is likely to act as a crucial antitumoral factor regarding glioma progression. Interplay between miR200a and MGMT should be considered as potential mechanism involved in therapeutic response.
authors.affiliation: Aix Marseille Université; Inserm; CRO2 UMR_S 911; Marseille, France.
authors.forename: Yolande
authors.initials: Y
authors.lastname: Berthois
authors.affiliation: Aix Marseille Université; Inserm; CRO2 UMR_S 911; Marseille, France.
authors.forename: Christine
authors.initials: C
authors.lastname: Delfino
authors.affiliation: Aix Marseille Université; Inserm; CRO2 UMR_S 911; Marseille, France; Departement de Neuropathologie; APHM; Hopital Timone; Marseille, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Metellus
authors.affiliation: Service de Transfert d'Oncologie Biologique; APHM; Hopital Nord; Marseille, France.
authors.forename: Frederic
authors.initials: F
authors.lastname: Fina
authors.affiliation: Service de Transfert d'Oncologie Biologique; APHM; Hopital Nord; Marseille, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Nanni-Metellus
authors.affiliation: Aix Marseille Université; Inserm; CRO2 UMR_S 911; Marseille, France.
authors.forename: Hayat
authors.initials: H
authors.lastname: Al Aswy
authors.affiliation: Aix Marseille Université; Inserm; CRO2 UMR_S 911; Marseille, France.
authors.forename: Victor
authors.initials: V
authors.lastname: Pirisi
authors.affiliation: Aix Marseille Université; Inserm; CRO2 UMR_S 911; Marseille, France; Service de Transfert d'Oncologie Biologique; APHM; Hopital Nord; Marseille, France.
authors.forename: L'Houcine
authors.initials: L
authors.lastname: Ouafik
authors.affiliation: Aix Marseille Université; Inserm; CRO2 UMR_S 911; Marseille, France.
authors.forename: Françoise
authors.initials: F
authors.lastname: Boudouresque
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000378:metabolism / Q000473:pathology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D015254:DNA Modification Methylases / Q000378:metabolism*; D045643:DNA Repair Enzymes / Q000378:metabolism*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D005260:Female; D005909:Glioblastoma / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D060787:Neoplasm Grading; D000077204:Temozolomide; D059467:Transcriptome; D025521:Tumor Suppressor Proteins / Q000378:metabolism*
chemical_list: D018906:Antineoplastic Agents, Alkylating; C533896:MIRN200 microRNA, human; C524940:MIRN21 microRNA, human; D035683:MicroRNAs; D025521:Tumor Suppressor Proteins; D003606:Dacarbazine; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes; D000077204:Temozolomide
keywords: O6-methylguanine methyltransferase; chemoresistance; glioblastoma; miR-200a-3p; miR21; microRNA; temozolomide
references.citation: Cell Signal. 2009 Apr;21(4):597-608
references.pmid: 19166930
references.citation: PLoS One. 2010 May 14;5(5):e10630
references.pmid: 20498843
references.citation: Biomed Pharmacother. 2010 Jul;64(6):399-408
references.pmid: 20363096
references.citation: Cell Res. 2008 May;18(5):549-57
references.pmid: 18379589
references.citation: Brain Res. 2010 Sep 17;1352:255-64
references.pmid: 20633539
references.citation: J Mol Med (Berl). 2011 Mar;89(3):303-15
references.pmid: 21340685
references.citation: Clin Transl Oncol. 2007 Mar;9(3):155-60
references.pmid: 17403626
references.citation: J Natl Cancer Inst. 2012 Apr 4;104(7):528-40
references.pmid: 22395642
references.citation: Cancer. 2013 Feb 15;119(4):814-24
references.pmid: 22990979
references.citation: Cancer Res. 2010 May 1;70(9):3606-17
references.pmid: 20388782
references.citation: Integr Biol (Camb). 2012 Oct;4(10):1237-55
references.pmid: 22892544
references.citation: Cancer Lett. 2013 May 28;332(2):237-48
references.pmid: 22261329
references.citation: Dev Biol. 2007 Feb 1;302(1):1-12
references.pmid: 16989803
references.citation: J Mol Diagn. 2006 May;8(2):209-17
references.pmid: 16645207
references.citation: Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8
references.pmid: 16039986
references.citation: Brain Tumor Pathol. 2011 Jul;28(3):209-14
references.pmid: 21618027
references.citation: Neuro Oncol. 2010 Jan;12(1):28-36
references.pmid: 20150365
references.citation: Endocrinology. 2013 Mar;154(3):1247-59
references.pmid: 23384836
references.citation: Cancer Res. 2005 Aug 15;65(16):7429-35
references.pmid: 16103096
references.citation: Mol Cell Biol. 2009 Nov;29(21):5923-40
references.pmid: 19703993
references.citation: Cancer Res. 2007 May 1;67(9):4467-73
references.pmid: 17483362
references.citation: Radiat Oncol. 2011 Nov 10;6:153
references.pmid: 22074483
references.citation: Cancer Res. 2007 Sep 15;67(18):8699-707
references.pmid: 17875710
references.citation: Neuro Oncol. 2013 Jun;15(6):691-706
references.pmid: 23482671
references.citation: Biomark Insights. 2006;2:113-121
references.pmid: 18079988
references.citation: Clin Cancer Res. 2009 Aug 15;15(16):5060-72
references.pmid: 19671845
references.citation: Neuro Oncol. 2010 Jul;12(7):725-35
references.pmid: 20364023
references.citation: Lancet Oncol. 2009 May;10(5):459-66
references.pmid: 19269895
references.citation: J Exp Med. 2011 May 9;208(5):875-83
references.pmid: 21518799
references.citation: Cancer Res. 2009 Aug 15;69(16):6704-12
references.pmid: 19654291
references.citation: Epigenomics. 2012 Aug;4(4):369-81
references.pmid: 22920178
references.citation: J Neurooncol. 2009 Jul;93(3):325-32
references.pmid: 19159078
references.citation: Endocr Relat Cancer. 2010 Dec 21;18(1):85-95
references.pmid: 21051560
references.citation: Cell. 2009 Aug 7;138(3):592-603
references.pmid: 19665978
references.citation: BMC Cancer. 2010 Jan 31;10:27
references.pmid: 20113523
references.citation: Cancer Res. 2007 Oct 1;67(19):8994-9000
references.pmid: 17908999
references.citation: EMBO Rep. 2008 Jun;9(6):582-9
references.pmid: 18483486
references.citation: Cancer Res. 2010 Nov 15;70(22):9243-52
references.pmid: 20935218
references.citation: Neurotherapeutics. 2009 Jul;6(3):447-57
references.pmid: 19560735
references.citation: J Biol Chem. 2010 Dec 17;285(51):39759-67
references.pmid: 20870728
references.citation: Biochim Biophys Acta. 2010 Nov;1803(11):1231-43
references.pmid: 20619301
references.citation: Int J Cancer. 2011 Mar 15;128(6):1327-34
references.pmid: 20473948
references.citation: BMC Cancer. 2013 Mar 22;13:147
references.pmid: 23522185
references.citation: J Invest Dermatol. 2009 Jul;129(7):1740-51
references.pmid: 19212343
references.citation: J Neurochem. 2012 Jul;122(2):444-55
references.pmid: 22564186
references.citation: J Clin Oncol. 2007 Apr 20;25(12):1470-5
references.pmid: 17442989
references.citation: Neoplasia. 2010 Sep;12(9):727-39
references.pmid: 20824049
references.citation: Anticancer Res. 2012 Jul;32(7):2835-41
references.pmid: 22753745
references.citation: Oncology. 2010;78(2):103-14
references.pmid: 20357518
references.citation: J Neurooncol. 2013 Nov;115(2):169-78
references.pmid: 23943501
references.citation: J Transl Med. 2013 Jan 09;11:10
references.pmid: 23302469
references.citation: Nat Cell Biol. 2008 May;10(5):593-601
references.pmid: 18376396
references.citation: J Int Med Res. 2014 Feb;42(1):164-72
references.pmid: 24326954
references.citation: Clin Cancer Res. 2007 Apr 1;13(7):2038-45
references.pmid: 17404084
references.citation: Int J Cancer. 2012 Nov 15;131(10):2215-22
references.pmid: 22618667
references.citation: Blood. 2010 Aug 12;116(6):945-52
references.pmid: 20393129
references.citation: Cancer. 2009 Oct 15;115(20):4783-94
references.pmid: 19637364
references.citation: Br J Cancer. 2010 Jun 29;103(1):29-35
references.pmid: 20517307
references.citation: Cancer Res. 2004 Jun 1;64(11):3807-13
references.pmid: 15172987
references.citation: Cancer Res. 2008 Oct 1;68(19):8164-72
references.pmid: 18829576
references.citation: Clin Cancer Res. 2002 Aug;8(8):2725-34
references.pmid: 12171906
references.citation: J Neurooncol. 2013 Jan;111(1):71-81
references.pmid: 23104517
references.citation: AAPS J. 2009 Dec;11(4):682-92
references.pmid: 19842044
references.citation: Cancer Res. 2001 Sep 15;61(18):6885-91
references.pmid: 11559565
references.citation: Mol Cancer Ther. 2010 May;9(5):1208-18
references.pmid: 20457618
references.citation: J Neurooncol. 2011 Mar;102(1):1-7
references.pmid: 20593219
references.citation: Am J Pathol. 2003 Sep;163(3):1033-43
references.pmid: 12937144
references.citation: Cancer Sci. 2011 Dec;102(12):2186-90
references.pmid: 21895872